EPO and perinatal asphyxia: In conclusion, in this trial, the administration of multiple high doses of EPO during the first week of life to neonates undergoing TH for moderate or severe HIE did not reduce the risk of death or neurodevelopmental impairment compared with placebo; a higher number of serious adverse events was also noted.